Myeloma Patients Europe
Budget
€1,746,111
EP Access
0
accredited persons
Staff
3
0.45 FTE
EU Grants
€57,774
Mission & Goals
Myeloma Patients Europe (MPE) is an umbrella organisation of myeloma and AL amyloidosis patient groups and associations from across Europe. MPE has a number of broad aims including: -Collaborating on projects to the benefit of the myeloma community -Exchanging information and best practice -Helping to develope existing patient groups and encouraging and facilitating the setting up of new groups -Helping to shape appropriate health-related policies and initiatives on a European and national level -Ensuring patients across Europe receive timely access to new treatment -Stimulating and promoting patient-centred research and clinical trials -Developing a strong evidence base for the needs and wants of patients and their role in research -Providing information, educational and outreach programmes to member groups
EU Legislative Interests
• Europe’s Beating Cancer Plan • Pharmaceutical Strategy for Europe • Regulation of the Parliament and European Council on Health Technology Assessment • Clinical Trials Regulation • Directive on the application of patients’ rights in cross-border healthcare
Interests Represented
Does not represent commercial interests
Member Of
• Rare Cancers Europe: Rare Cancers Europe | Rare Cancers Europe - https://www.rarecancerseurope.org/ • EUROBLOODNET ePAG: European Patient Advocacy Group in Hematology | EuroBloodNet - https://eurobloodnet.eu/patientsadvocacy/epag/ • European Cancer Organisation Patient Advisory Committee (ECO PAC): Patients - European Cancer Organisation - https://www.europeancancer.org/patients • European Haematology Association (EHA) PAC • EURORDIS: EURORDIS - The Voice of Rare Disease Patients in Europe - https://www.eurordis.org/ • HTA Stakeholder network
Organisation Members
https://www.mpeurope.org/about-mpe/our-members/
Commissioner Meetings
No recorded meetings with EU commissioners.